Abstract:Objective: Through bioassay-guided natural product research, it has been discovered that oleanolic acid and its glycosides possess an antibone resorption activity. Quinoxaline derivative of oleanolic acid (QOA-8a), a novel compound, is sourced from a structural modification of oleanolic acid. The aim of the present study was to evaluate the activities of QOA-8a on bone resorption in vitro and its osteoprotective effect in vivo.Methods: Osteoclast precursors and mature osteoclasts were used to assay antibone resorption activities in vitro. RAW264.7 cells cultured for 2 days in the presence of the receptor activator for nuclear factor kappa B ligand were used as osteoclast precursors. Mature osteoclasts were generated from either primary cultures of mouse bone marrow-derived macrophages or RAW264.7 cells. Eight-week-old female mice that underwent either ovariectomy or sham surgical operation were used for the evaluation of the osteoprotective effect of QOA-8a at doses of 0.1, 1, and 10 mg kg(-1) day(-1).Results: QOA-8a significantly inhibited the differentiation, formation, and bone resorptive activity of mature osteoclasts without cytotoxicity. QOA-8a selectively induced apoptosis at an early stage of mature osteoclasts at least via increasing the caspase-3 activity, but not osteoclast precursors. Furthermore, QOA-8a significantly prevented bone loss in ovariectomized mice without any hormone-like adverse effects, whereas the mice treated with 1 mg kg(-1) day(-1) kept the same bone mineral density level as that of the sham mice.Conclusions: QOA-8a inhibits bone resorption without cytotoxicity and prevents bone loss without any hormone-like adverse effects. Although further investigations are necessary to elucidate the detailed molecular mechanisms, QOA-8a demonstrates great potential as a novel agent for the treatment of osteoporosis.

Discovery of Novel Neo -Clerodane Derivatives as Potent Dual-Functional Antiosteoporosis Agents through Targeting Peroxisome Proliferator-Activated Receptor-γ

Design and Synthesis of Novel Dehydroepiandrosterone Analogues As Potent Antiproliferative Agents

Novel heterocyclic ring-fused oleanolic acid derivatives as osteoclast inhibitors for osteoporosis

Discovery of Novel Antiosteoporosis Leads with Bone Resorption Inhibition and Anabolic Promotion through a Chemotype-Assembly Approach

Synthesis and Biological Evaluation of Heterocyclic Ring-Fused 20( S )-Protopanaxadiol Derivatives as Potent Antiosteoporosis Agents

Synthesis of Heterocyclic Ring-Fused Bisnoralcohol Derivatives as Novel Small-Molecule Antiosteoporosis Agents

Identifying Marine-Derived Tanzawaic Acid Derivatives as Novel Inhibitors against Osteoclastogenesis and Osteoporosis via Downregulation of NF-κB and NFATc1 Activation

12-Deoxyphorbol 13-Acetate Inhibits RANKL-induced Osteoclastogenesis Via the Attenuation of MAPK Signaling and NFATc1 Activation

Identification of Novel Cannabinoid CB2 Receptor Agonists from Botanical Compounds and Preliminary Evaluation of Their Anti-Osteoporotic Effects

Synthesis of N-methylpyridine-chlorofuranformamide analogs as novel OPG up-regulators and inhibitors of RANKL-induced osteoclastogenesis

Design, Synthesis, and Biological Evaluation of Novel Phenol Ether Derivatives As Non-Covalent Proteasome Inhibitors.

[Should we modernize the health system?].

Design, Synthesis and Biological Evaluation of Novel Non-peptide Boronic Acid Derivatives As Proteasome Inhibitors

A Novel Diterpenoid Suppresses Osteoclastogenesis and Promotes Osteogenesis by Inhibiting Ifrd1-Mediated and IκBα-Mediated p65 Nuclear Translocation.

Identification of novel RANKL inhibitors through in silico analysis

Synthesis and evaluation of 2-NMPA derivatives as potential agents for prevention of osteoporosis in vitro and in vivo

Relative and Absolute Structures of Diospongin A, B and C

Synthesis and biological evaluation of pyrazole-fused oleanolic acid derivatives as novel inhibitors of inflammatory and osteoclast differentiation

Briarane-type diterpenoids, the inhibitors of osteoclast formation by interrupting Keap1-Nrf2 interaction and activating Nrf2 pathway

Natural Germacrane Sesquiterpenes Inhibit Osteoclast Formation, Bone Resorption, RANKL-Induced NF-κB Activation, and IκBα Degradation

Quinoxaline Derivative of Oleanolic Acid Inhibits Osteoclastic Bone Resorption and Prevents Ovariectomy-Induced Bone Loss